SARCOMA

The combination of doxorubicin, balstilimab, and zalifrelimab has some early signals of activity in both immune hot and cold sarcoma subtypes with manageable toxicity.

Correlative work is ongoing following positive results from the phase 1 study of cabozantinib with nivolumab and ipilimumab.

No progression-free survival advantage was shown with milademetan compared with trabectedin in the phase 3 MANTRA study.

According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.

A patient treated with the second highest dose level of FHD-609 had a grade 4 adverse event. Enrollment in the study of the agent in patients with synovial sarcoma or SMARCB-1 deleted tumors has been halted.

TP-1287, an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib, has been granted an orphan drug designation by the FDA for patients with Ewing sarcoma.

Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.

In an interview with Targeted Oncology, Neeta Somaiah, MD, explained how targeted therapies have started to re-shape the treatment of sarcomas and the potential role of immunotherapy in the future.

Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.

A phase 1 trial showed efficacy of a novel T-cell therapy targeting MAGE-A4 in solid tumors, particularly synovial sarcoma.

In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.

Investigators in the IT-01 trial of INT230-6 as monotherapy or combined with ipilimumab showed safety and potential efficacy in patients with sarcoma.

With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.

Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.

A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

The FDA has granted an orphan drug designation to DUNP19 for patients with osteosarcoma.

The FDA granted an orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.

Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.

For sarcoma awareness month, Lisa Ercolano, MD, discusses the need for a multidisciplinary approach to treating patients with osteosarcoma.

The FDA has approved crizotinib as treatment for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.

IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.

With expanding knowledge of the molecular characteristics of uterine sarcomas, investigators are working to develop treatments specific to each subtype.

Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.

Pembrolizumab may be a new therapeutic option for patients classic and endemic Kaposi’s sarcoma, according to phase 2 study results.

Orphan drug designation has been granted to Veyonda as a form of treatment in patients with soft tissue sarcoma.

Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.

There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.

For patients with advanced synovial sarcoma or myxoid/ round cell liposarcoma, afamitresgene autoleucel is a promising novel therapy.

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.